Loading market dashboard
Bolt Biotherapeutics, Inc.
BOLTHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $5.8 per share a year ago.
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 22,704 shares, a growth of 355.3% from the March 31st total of 4,987 shares. Based on an average daily volume of 21,902 shares,
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks Consensus Estimate of a loss of $4.3. This compares to a loss of $7.6 per share a year ago.
REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update.
